Arishya Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Arishya Sharma has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alexandru Almasan
Department of Cancer Biology, Lerner Research Institute, Cleveland, USA
1 shared publication - Brian P. Rubin
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
1 shared publication - Cristina Magi-Galluzzi
Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH
1 shared publication - Donna Elizabeth Hansel
University of California San Diego
1 shared publication - Eric A. Klein
GRAIL, Inc, Menlo Park, CA
1 shared publication - Judith A. Drazba
Imaging Core, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH, United States, 44195, USA
1 shared publication
Latest Publications
- Open Access
- 23 March 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 70
Autophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
Macroautophagy is a catabolic process that can mediate cell death or survival. Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment (TR) is known to induce autophagy. Here we investigated whether SQSTM1/p62 (p62) overexpression, as a marker of autophagic flux, was related to aggressiveness of human prostate cancer (PCa) and whether autophagy regulated the treatment response in sensitive but not resistant PCa cell lines.
- 23 March 2014
- Published by Springer Nature in Molecular Cancer
- Vol. 13 (1) , 70
Open AccessAutophagic flux determines cell death and survival in response to Apo2L/TRAIL (dulanermin)
Macroautophagy is a catabolic process that can mediate cell death or survival. Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) treatment (TR) is known to induce autophagy. Here we investigated whether SQSTM1/p62 (p62) overexpression, as a marker of autophagic flux, was related to aggressiveness of human prostate cancer (PCa) and whether autophagy regulated the treatment response in sensitive but not resistant PCa cell lines.